HLA-matched sibling bone marrow transplantation for β-thalassemia major

Blood

Volumn 117, Issue 5, 2011, Pages 1745-1750

  Sabloff, Mitchell ^a   Chandy, Mammen ^b   Wang, Zhiwei ^c   Logan, Brent R ^c   Ghavamzadeh, Ardeshir ^d   Li, Chi Kong ^e   Irfan, Syed Mohammad ^f   Bredeson, Christopher N ^c   Cowan, Morton J ^g   Gale, Robert Peter ^h   Hale, Gregory A ⁱ   Horan, John ^j   Hongeng, Suradej ^k   Eapen, Mary ^c   Walters, Mark C ^l  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF TEHRAN   (Iran)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f National Institute of Blood Disease and Bone Marrow Transplantation   (Pakistan)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h CELGENE CORPORATION   (United States)

ⁱ JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^j Children's Healthcare of Atlanta at Egleston   (United States)

^k MAHIDOL UNIVERSITY   (Thailand)

^l CHILDREN S HOSPITAL OAKLAND   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA ANTIGEN; METHOTREXATE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BETA THALASSEMIA MAJOR; BLEEDING; BONE MARROW TRANSPLANTATION; CHELATION THERAPY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEPATOMEGALY; HUMAN; INTERSTITIAL PNEUMONIA; IRON CHELATION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; MYELOABLATIVE CONDITIONING; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETRANSPLANTATION; RISK ASSESSMENT; SCHOOL CHILD; SIBLING; THROMBOCYTE COUNT; TREATMENT OUTCOME; VEIN OCCLUSION;

EID: 79551639277     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-306829     Document Type: Article

References (40)

1. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-1146.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193. (Pubitemid 39390442)
3. Morris CR, Singer ST, Walters MC. Clinical hemoglobinopathies: iron, lungs and new blood. Curr Opin Hematol. 2006;13(6):407-418.
4. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417-421. (Pubitemid 20059509)
5. Angelucci E, Baronciani D. Allogeneic stem cell transplantation for thalassemia major. Haematologica. 2008;93(12):1780-1784.
6. Gaziev J, Sodani P, Lucarelli G. Hematopoietic stem cell transplantation in thalassemia. Bone Marrow Transplant. 2008;42[suppl 1]:S41.
7. Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104(4):1201-1203. (Pubitemid 39038044)
8. Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia: the experience of Pesaro. Ann N Y Acad Sci. 1998;850:270-275. (Pubitemid 28369767)
9. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. 1993;329(12):840-844. (Pubitemid 23267211)
10. Giardini C, Galimberti M, Lucarelli G, Polchi P, Baronciani D, Angelucci E. Bone marrow transplantation in class 2 thalassemia patients. Bone Marrow Transplant. 1993;12[suppl 1]:59-62. (Pubitemid 23231061)
11. Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia: the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant. 2005;36(10):839-845. (Pubitemid 41655608)
12. Ullah K, Khan B, Raza S, et al. Bone marrow transplant cure for beta-thalassaemia major: initial experience from a developing country. Ann Hematol. 2008;87(8):655-661.
13. Boulad F, Giardina P, Gillio A, et al. Bone marrow transplantation for homozygous beta-thalassemia: the Memorial Sloan-Kettering Cancer Center experience. Ann N Y Acad Sci. 1998;850:498-502. (Pubitemid 28369815)
14. Walters MC, Sullivan KM, O'Reilly RJ, et al. Bone marrow transplantation for thalassemia: the USA experience. Am J Pediatr Hematol Oncol. 1994;16(1):11-17. (Pubitemid 24046451)
15. Chern JP, Su S, Lin KH, et al. Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan. Pediatr Blood Cancer. 2007;48(5):550-554. (Pubitemid 46496351)
16. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462.
17. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855-864.
18. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am. 1999;13(5):1091-1112.
19. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-3737.
20. Maggio A, Vitrano A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009;42(3):247-251.
21. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054:40-47.
22. Mathews V, George B, Deotare U, et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with beta thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(8):889-894. (Pubitemid 47055393)
23. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood. 1996;87(5):2082-2088. (Pubitemid 26068926)
24. Hongeng S, Pakakasama S, Chuansumrit A, et al. Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. Am J Hematol. 2007;82(12):1095-1098.
25. Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult thalassemic patients. Blood. 1999;93(4):1164-1167. (Pubitemid 29076130)
26. Pawlowska AB, Blazar BR, Angelucci E, Baronciani D, Shu XO, Bostrom B. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant. 1997;20(11):915-920.
27. Bornhauser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003;102(3):820-826.
28. Chiesa R, Cappelli B, Crocchiolo R, et al. Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: limited toxicity with a dose-adjustment policy. Biol Blood Marrow Transplant. 2010;16(5):622-628.
29. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25(1):55-61.
30. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant. 2007;13(7):853-862.
31. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101(5):2043-2048.
32. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8(9):468-476.
33. Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood. 2010;115(22):4597-4604.
34. Cappelli B, Chiesa R, Evangelio C, et al. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous busulphan. Br J Haematol. 2009;147(4):554-560.
35. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104(3):857-864.
36. Gaziev J, Sodani P, Lucarelli G, et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant. 2008;42(6):397-404.
37. Stepensky P, Or R, Shapira MY, Revel-Vilk S, Stein J, Resnick IB. Second bone marrow transplantation for patients with thalassemia: risks and benefits. Haematologica. 2009;94(9):1329-1330.
38. Shenoy S, Grossman WJ, DiPersio J, et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35(4):345-352. (Pubitemid 40309479)
39. Karimi M, Jamalian N. Sociocultural challenges of thalassemia birth in Islamic and developing countries. J Pediatr Hematol Oncol. 2008;30(4):335. (Pubitemid 351507593)
40. Weatherall DJ. Keynote address: the challenge of thalassemia for the developing countries. Ann N Y Acad Sci. 2005;1054:11-17. (Pubitemid 43031005)